United States
DAPH
EGFR inhibitor
| BML-EI386-0005 | 5 mg | 112.00 USD |  |
||
DAPH abolishes or greatly reduces previously existing fully formed β-amyloid (1-42) fibrils and eliminates β-amyloid (1-42) peptide neurotoxicity. Also inhibits EGFR kinase. IC50 for inhibition of β-sheet content of aggregated β-amyloid (1-42) is 4.5µM.
Product Specification
| Alternative Name: | 4,5-Dianilinophthalimide, CGP-52411 |
| Formula: | C20H15N3O2 |
| MW: | 329.4 |
| Purity: | ≥98% (TLC) |
| Appearance: | Orange solid. |
| CAS: | 145915-58-8 |
| Solubility: | Soluble in DMSO (25mg/ml). |
| Long Term Storage: | -20°C |
| Background / Technical Information: | Please click here for the comprehensive product data sheet. |
Please mouse over
Product Toolbox
PRODUCT RESOURCES
Datasheet
MSDS
RELATED PRODUCTS
By catalog section:
By biological activity:
EGFR InhibitorAmyloid beta Inhibitor
PRODUCT SUPPORT
Technical ServiceBulk Quantity Quote
Customer Service
Related Literature
Scientific Posters
Disease-Associated Stress Signaling
Add to order list
 |
20-Sep-10 |
| Download as PDF | |
TOPIX Newsletters
TOPIX I/09 - Product Newsletter from Enzo Life Sciences
Add to order list
 |
01-Jan-09 |
| Download as PDF | |
